Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091681 | 1.00 | CMA1 (0.44) | CMA1CTSLCTSKCTSBLMNA | |
| SCHEMBL12012605 | 1.00 | CMA1 (0.44) | CMA1CTSLCTSKCTSBLMNA | |
| SCHEMBL16143227 | 1.00 | CMA1 (0.44) | CMA1CTSLCTSKCTSBLMNA | |
| SCHEMBL464045 | 1.00 | CMA1 (0.44) | CMA1CTSLCTSKCTSBLMNA | |
| SCHEMBL464081 | 0.92 | CTSB (0.44) | CMA1CTSLCTSKCTSB | |
| SCHEMBL463921 | 0.92 | CTSB (0.44) | CMA1CTSLCTSKCTSB | |
| SCHEMBL16143229 | 0.92 | CTSB (0.44) | CMA1CTSLCTSKCTSB | |
| SCHEMBL13091688 | 0.92 | CTSB (0.44) | CMA1CTSLCTSKCTSB | |
| SCHEMBL12012606 | 0.92 | CTSB (0.44) | CMA1CTSLCTSKCTSB | |
| SCHEMBL16143988 | 0.89 | CTSK (0.50) | CTSLCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | CMA1 28/4885CTSL 5/4885CTSK 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.